Retatrutide

Category: Triple agonist (GIP/GLP-1/glucagon receptors)

Studied or approved for: Obesity and type 2 diabetes (clinical trials)

Regulatory status: INVESTIGATIONAL — in Phase 3 trials; NOT FDA-approved.

Typical administration: Weekly injection (trial setting)

Educational purposes only — not medical advice. Peptiverse.net does not sell or prescribe peptides. Consult a qualified healthcare professional. Full disclaimer: /disclaimer/.